Research in plain language

GHK-Cu

What it is

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a small peptide that occurs naturally in human plasma, saliva, and urine and declines with age. It has been studied mostly in cell culture and animals as a signal that can stimulate collagen and growth-factor production by fibroblasts, support wound healing and angiogenesis, and reduce oxidative-stress and inflammatory markers.

How studies used it

Model: In vitro, cultured human skin fibroblasts (cell culture, no body weight applicable)
Studied for: Collagen synthesis / skin matrix
Dose: Molar, not per-kg (in vitro): stimulation began at 10^-12 to 10^-11 M and was maximal at 10^-9 M (1 nM) GHK-Cu in the culture medium
Dosing: Single concentration added to culture medium across a dose range
Route: In vitro addition to cell-culture medium (no systemic route)
Duration: Not stated in the abstract

Effects measured: Dose-dependent increase in collagen synthesis by the fibroblasts; the effect was independent of any change in cell number (so it reflected more biosynthetic activity per cell, not more cells). The abstract reports no exact percentage or fold-increase for the magnitude.

Side effects: No adverse events reported in this study (in vitro)

Sources: Maquart FX et al., FEBS Lett 1988

Model: In vitro, primary human dermal fibroblasts from previously irradiated patients vs normal fibroblasts (cell culture, no body weight applicable)
Studied for: Fibroblast recovery after radiation / growth-factor expression
Dose: Molar, not per-kg (in vitro): 1 x 10^-9 mol/L (1 nM) GHK-Cu in serum- and growth-factor-free medium
Dosing: Single 1 nM concentration in the culture medium
Route: In vitro addition to cell-culture medium (no systemic route)
Duration: Not stated in the abstract

Effects measured: Treated irradiated fibroblasts had faster population-doubling times than untreated irradiated controls and roughly matched the growth rate of untreated normal fibroblasts. Early after exposure, treated irradiated cells produced significantly more basic FGF (bFGF) and VEGF than untreated controls.

Side effects: No adverse events reported in this study (in vitro)

Sources: Pollard JD et al., Arch Facial Plast Surg 2005

Model: Ex vivo human skin from cadavers (stratum corneum, epidermis, dermatomed skin) in flow-through diffusion cells (no body weight applicable)
Studied for: Topical skin penetration and retention of copper from GHK-Cu (anti-inflammatory delivery question)
Dose: Topical percentage, not per-kg (ex vivo): 0.68% aqueous copper as the tripeptide (glycyl-L-histidyl-L-lysine cuprate diacetate) applied to 1 cm^2 of isolated skin
Dosing: Single topical application to the skin surface
Route: Topical (in vitro transdermal diffusion-cell)
Duration: 48 hours

Effects measured: Permeability coefficient through dermatomed skin was 2.43 +/- 0.51 x 10^-4 cm/h; 136.2 +/- 17.5 ug/cm^2 of copper permeated through 1 cm^2 over 48 h, and 82 +/- 8.1 ug/cm^2 of copper was retained in the tissue as a depot. Shows copper from GHK-Cu both penetrates and accumulates in skin.

Side effects: No adverse events reported in this study (ex vivo human skin)

Sources: Hostynek JJ et al., Inflamm Res 2010

Model: Mouse (C57BL/6J) with cigarette-smoke-induced emphysema, plus human A549 alveolar cells in vitro
Studied for: Cigarette-smoke-induced pulmonary emphysema and lung inflammation / oxidative stress
Dose: 0.2, 2 and 20 ug/g/day, i.e. 0.2, 2 and 20 mg/kg/day (ug/g equals mg/kg directly); highest dose 20 mg/kg
Dosing: Intraperitoneal injection on alternate days, started after smoke exposure began
Route: Intraperitoneal (mouse); cell-culture addition for the A549 arm
Duration: 12 weeks of cigarette-smoke exposure

Effects measured: GHK-Cu reduced emphysematous changes and restored the MMP-9/TIMP-1 balance, lowered inflammatory cytokines IL-1beta and TNF-alpha, lowered oxidative markers MPO and MDA, and raised antioxidant measures (T-AOC and GSH). It suppressed NF-kB and increased Nrf2 antioxidant signaling. In A549 cells exposed to cigarette-smoke extract, GHK-Cu reduced oxidative stress via Nrf2 upregulation. Magnitudes per dose are not all given in the abstract.

Side effects: No adverse events reported in this study

Sources: Zhang Q et al., Front Mol Biosci 2022

Model: Mouse with scald (thermal) wounds, plus human umbilical vein endothelial cells (HUVEC) in vitro
Studied for: Scald wound healing / angiogenesis (liposomal GHK-Cu formulation)
Dose: Not reported as mg/kg or molar in the abstract; GHK-Cu was delivered as nanoscale liposomes (GHK-Cu-liposomes), but no body-weight dose or culture concentration is stated
Dosing: Topical application of the liposomal formulation to the wounds (frequency not stated in the abstract)
Route: Topical (mouse wounds); cell-culture addition for the HUVEC arm
Duration: Wounds followed to healing; healing completed by 14 days post-injury in treated animals

Effects measured: GHK-Cu-liposomes increased HUVEC proliferation by about 33.1% and raised VEGF, FGF-2, CDK4 and CyclinD1 expression. In the mouse scald model the liposomal form produced more angiogenesis than free GHK-Cu, with higher CD31 and Ki67 immunofluorescence, and wounds healed by day 14. No control-vs-treated closure percentages are given in the abstract.

Side effects: No adverse events reported in this study

Sources: Wang X et al., Wound Repair Regen 2017

Model: Rat (Sprague-Dawley), dorsal skin irradiated then surgical flap (irradiated wound model)
Studied for: Wound healing in irradiated skin flaps (flap ischemia, blood-vessel number, VEGF)
Dose: Topical, not per-kg: GHK-Cu gel applied to the flap wound (gel concentration not stated as a per-kg dose); control group received aquaphilic ointment
Dosing: Topical application twice daily
Route: Topical (gel)
Duration: 10 days of treatment (after irradiation and a 28-day recovery before flap creation)

Effects measured: Negative result. The GHK-Cu group (n=13) had a significantly LARGER mean ischemic area than controls (n=10): 5.0 cm^2 vs 3.8 cm^2 (P=0.011), i.e. worse on this measure. No significant difference in blood-vessel number (209.0 vs 207.4, P=0.973), vessel luminal area (525.7 vs 422.8 um^2, P=0.118), or VEGF intensity score (0.34 vs 0.54, P=0.169). Authors concluded topical GHK-Cu showed no benefit for flap ischemia, vessels, or VEGF in this model.

Side effects: No specific adverse events reported beyond the larger ischemic area observed in the treated group

Sources: Parker NP et al., Otolaryngol Head Neck Surg 2013

How solid the evidence is

The evidence base for GHK-Cu is overwhelmingly preclinical: cell-culture (in vitro) work, ex-vivo human cadaver skin, and rodent studies. There are no controlled human dosing trials here, and no established human dosing protocol exists. Because the strongest mechanistic data are in vitro, the active concentrations are reported as molar (around 1 nM, 10^-9 M) and are NOT convertible to a per-kg human dose; treating an in-vitro nanomolar concentration as a body-weight dose would be wrong. The only clean per-kg figures come from one mouse emphysema study (Zhang 2022: 0.2 / 2 / 20 mg/kg/day intraperitoneal, since ug/g equals mg/kg), which is a non-skin indication and a route nobody uses cosmetically. Skin and wound studies used topical concentrations (e.g. 0.68% copper ex vivo) rather than systemic doses, and one liposomal wound study (Wang 2017) reported no quantified dose at all. Importantly, the evidence is not uniformly positive: a rat irradiated-flap study (Parker 2013) found topical GHK-Cu gave no benefit and a significantly larger ischemic area than control (5.0 vs 3.8 cm^2, P=0.011), so wound-healing claims are not consistent across models. Two of the most cited overviews (Pickart 2015, Pickart 2018) are narrative reviews co-authored by Loren Pickart, who holds commercial/patent interests in GHK-Cu skincare, which is a clear conflict-of-interest and means their broad gene-regulation claims should be read cautiously rather than as established fact. Bottom line: GHK-Cu has plausible, repeatedly observed in-vitro and animal effects on collagen, growth factors, angiogenesis, and oxidative-stress markers, but human efficacy, safety, and dosing for any indication are not established, and at least one animal wound study was negative.

Sources

Study data, research use only. No established human dosing protocol.